-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SwuGSY4t2guN3ipNbgL5FnAyXGMBad8CWRESimT6dg5IdRCCj/gSlkKGw/frlsgo /GoWXXKwg5nbGX4I8Qu0HQ== 0000891554-02-001414.txt : 20020415 0000891554-02-001414.hdr.sgml : 20020415 ACCESSION NUMBER: 0000891554-02-001414 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020321 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HBM BIOVENTURES AG CENTRAL INDEX KEY: 0001169566 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: ZUGERSTRASSE 50 STREET 2: 6340 BAAR CITY: SWITZERLAND STATE: V8 ZIP: 00000 MAIL ADDRESS: STREET 1: ZUGERSTRASSE 50 STREET 2: 6340 BAAR CITY: SWITZERLAND STATE: V8 ZIP: 00000 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TELIK INC CENTRAL INDEX KEY: 0001109196 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930987903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-60385 FILM NUMBER: 02581292 BUSINESS ADDRESS: STREET 1: 750 GATEWAY BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502449303 MAIL ADDRESS: STREET 1: 750 GATEWAY BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 SC 13G 1 d50095_sc13g.txt SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___)* Telik, Inc. (Name of Issuer) Common Stock, $.01 par value (Title of Class of Securities) 87959M 10 9 (CUSIP Number) March 11, 2002 (Date of Event which Requires filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [x] Rule 13d-1(c) [_] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 87959M 10 9 - -------------------------------------------------------------------------------- 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only) HBM BioVentures AG - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_] (b) [_] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Switzerland - -------------------------------------------------------------------------------- 5 SOLE VOTING POWER NUMBER OF 1,481,607 ------------------------------------------------------- SHARES 6 SHARED VOTING POWER BENEFICIALLY -0- ------------------------------------------------------- OWNED BY EACH 7 SOLE DISPOSITIVE POWER REPORTING 1,481,607 ------------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER WITH -0- - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,481,607 - -------------------------------------------------------------------------------- 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES Not Applicable. - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.34% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON CO - -------------------------------------------------------------------------------- 2 ITEM 1. (a) Name of Issuer: Telik, Inc. (b) Address of Issuer's Principal Executive Offices: 759 Gateway Boulevard, South San Francisco, CA 94080 ITEM 2. (a) Name of Person Filing: HBM BioVentures AG (b) Address of Principal Business Office or, if none, Residence: The following is the address of the principal business office of the filing person: Zugerstrasse 50 6340 Baar Switzerland (c) Citizenship: Switzerland (d) Title of Class of Securities: Common Stock, $.01 par value (e) CUSIP Number: 87959M 10 9 ITEM 3. If this Statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a: Not applicable. ITEM 4. Ownership (a) Amount Beneficially Owned: 1,481,607 (b) Percent of Class: 5.34% (c) Number of shares as to which the person has:. (i) Sole power to vote or to direct the vote 1,481,607 (ii) Shared power to vote or to direct the vote -0- (iii) Sole power to dispose or to direct the disposition 1,481,607 (iv) Shared power to dispose or to direct the disposition -0- 3 ITEM 5. Ownership of Five Percent or Less of a Class Not applicable. ITEM 6. Ownership of More than Five Percent on Behalf of Another Person Not applicable. ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company The shares beneficially owned by the Reporting Person and reported herein are owned directly by International BM Biomedicine Holdings Inc. and indirectly by the Reporting Person pursuant to Rule 13d-3(d)(1)(i). ITEM 8. Identification and Classification of Members of the Group Not applicable. ITEM 9. Notice of Dissolution of Group Not applicable. ITEM 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: March 21, 2002 /s/ Joachim Rudolf ------------------------------- By: Joachim Rudolf Title: Chief Financial Officer 4 -----END PRIVACY-ENHANCED MESSAGE-----